Xi-Yong (Sean) Fu, PhD, MBA
Interim Chief Executive Officer

Dr. Xi-Yong (Sean) Fu has served as our director since July 2024.

In addition to being Interim CEO and Director of I-Mab, Dr. Sean Fu is also an Operating Partner of ABio-X, an incubation platform for life sciences companies. Before joining ABio-X, Dr. Fu was co-founder and CEO of RVAC Medicines, an mRNA platform company. Prior to founding RVAC, Dr. Fu was Group VP and head of International R&D for Luye Pharma, overseeing organizations in Boston, Princeton, Germany, Switzerland, and Japan. He was also the CEO of GeneLeap, a Luye subsidiary company focused on DNA and RNA therapeutics. Previously, Dr. Fu worked at Merck & Co. for 15 years with responsibilities covering R&D, business development, finance, and operational management. His work at Merck included management of the finances for the late-stage clinical portfolio and leading the integration of the global R&D network following the landmark $42 billion merger between Merck and Schering-Plough. Dr. Fu earned a Master’s and PhD degrees in materials science and engineering from Ohio State University, and an MBA from the Wharton School of the University of Pennsylvania.

Phillip Dennis, MD, PhD
Chief Medical Officer

Before joining I-Mab, Dr. Dennis was Vice President of Lung Cancer Strategy and the Global Project Head for a novel, first-in-class ADC at Sanofi (NASDAQ: SNY). Prior to Sanofi, Dr. Dennis was Vice President of Lung Cancer Strategy and Global Clinical Lead at AstraZeneca (NASDAQ: AZN). In these roles, Dr. Dennis served as the disease strategy head for lung cancer and led the cross-functional development of key assets, including IMFINZI®. Prior to his pharmaceutical career, Dr. Dennis was a widely published professor of Oncology, Medicine, and Pharmacology at Johns Hopkins University. Dr. Dennis received his MS, MD, and PhD degrees from the New York University School of Medicine as part of the Medical Scientist Training Program. Dr. Dennis completed his residency in Internal Medicine and fellowship in Medical Oncology at Johns Hopkins. Dr. Dennis also spent 14 years as a translational researcher at the US National Cancer Institute, achieving tenure as a Senior Investigator. He is an elected member of the American Society for Clinical Investigation and has won several awards, including an NIH Merit Award.

Joseph Skelton
Chief Financial Officer

Joseph Skelton brings nearly ten years of investment banking experience with a focus on the life sciences vertical. During his career, he has advised on transactions totaling more than $20 billion.

Prior to joining I-Mab, Mr. Skelton served as a Senior Vice President in the Healthcare Investment Banking Group at Truist Securities, where he led the coverage efforts on the biopharma sector. During his tenure at Truist he focused on providing strategic and financial advice to life sciences companies. Prior to joining Truist, Mr. Skelton worked as an investment banker at Cantor covering the healthcare vertical. Mr. Skelton holds a M.S. and B.S. in Accounting and Business & Economics, respectively from Lehigh University.

Claire Xu, MD, PhD
Vice President, Clinical Development

Claire Xu, MD, PhD, was appointed as I-Mab’s Vice President, Clinical Development in April 2024 to lead clinical development, clinical operation, clinical biomarker, project management and regulatory affairs. Dr. Xu joined I-Mab in 2018 as our U.S. site head, leading the establishment of I-Mab’s Maryland site and the continual growth of I-Mab’s clinical team. Previously, Dr. Xu held roles of increasing responsibility in Early Phase Development and Translational Medicine at Otsuka Pharmaceutical Development & Commercialization, where she was responsible for designing and overseeing multiple phase 1/2 studies of different therapeutic areas, including hematology/oncology. Dr. Xu received her PhD in clinical pharmacology from Indiana University School of Medicine and her Bachelor of Medicine degree from Zhongshan School of Medicine, Sun Yat-sen University, China.